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(http://creativecommotality being particularly high. There is no cure for dementia; antidementia medications have been
shown to improve cognition and function, but their effect on mortality in real-world settings is little
known. This study examines associations between treatment with antidementia medication and mor-
tality in older people with dementia after an emergency admission.
Methods: The design is a retrospective cohort study of people aged 65 years, with a diagnosis of
dementia and an emergency hospital admission between 01/01/2010 and 31/12/2016. Two classes of
antidementia medication were considered: the acetylcholinesterase inhibitors and memantine. Mor-
tality was examined using a Cox proportional hazards model with time-varying covariates for the pre-
scribing of antidementia medication before or on admission and during one-year follow-up, adjusted
for demographics, comorbidity, and community prescribing including anticholinergic burden. Pro-
pensity score analysis was examined for treatment selection bias.
Results: There were 9142 patients with known dementia included in this study, of which 45.0%
(n5 4110) received an antidementia medication before or on admission; 31.3% (n5 2864) were pre-
scribed one of the acetylcholinesterase inhibitors, 8.7% (n 5 798) memantine, and 4.9% (n 5 448)
both. 32.9% (n 5 1352) of these patients died in the year after admission, compared to 42.7%
(n5 2148) of those with no antidementia medication on admission. The Cox model showed a signif-
icant reduction in mortality in patients treated with acetylcholinesterase inhibitors (hazard ratio
[HR] 5 0.78, 95% CI 0.72–0.85) or memantine (HR 5 0.75, 95% CI 0.66–0.86) or both
(HR5 0.76, 95% CI 0.68–0.94). Sensitivity analysis by propensity score matching confirmed the as-
sociations between antidementia prescribing and reduced mortality.
Discussion: Treatment with antidementia medication is associated with a reduction in risk of death in
the year after an emergency hospital admission. Further research is required to determine if there is a
causal relationship between treatment and mortality, and whether “symptomatic” therapy for demen-
tia does have a disease-modifying effect.
 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
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With the aging population, the number of people living
with dementia is forecasted to increase [1]. Dementia is
known to shorten life expectancy [2], and there is currently
no known cure or disease-modifying treatment. Symptomatic
treatment is available for those with dementia due to Alz-
heimer’s disease (AD). Two classes of medication are
currently licensed: the acetylcholinesterase inhibitors
(AChEIs: donepezil, galantamine, and rivastigmine) and the
N-methyl-D-aspartate receptor antagonist, memantine [3–5].
The efficacy of these medications has been demonstrated in
randomized controlled clinical trials, with most of them
showing associations between antidementia drug use and
improved cognition and functional ability [5–13]. In
addition, some trials have shown prolonged independence
and home living in people on antidementia medication
compared to placebo [14–16]. Observational studies
investigating long-term therapeutic effects of antidementia
drugs in real-world settings have shown a reduced decline
in cognition and function in those treated with antidementia
medication [17,18]. In 2011, NICE suggested that evidence
of improvement in clinically meaningful outcomes for these
medications was lacking [19]. In a recent systematic review
and meta-analysis of randomized placebo-controlled clinical
trials, the use of AChEIs was associated with reduced mortal-
ity [20], and the authors suggest this finding may indicate
some disease-modifying effect of these drugs. This finding
however is not consistent across all studies: some studies
show a reduction in mortality in people who were prescribed
antidementia medication [18,21–23], one study shows a
reduction in cardiovascular deaths [24], and another has failed
to find an association [15].
It has been shown that mortality in people with demen-
tia is not associated with disease severity, cognitive func-
tion, or functional ability [2], and we can therefore
postulate that other factors in addition to disease progres-
sion may have a role. Most people with dementia die
either in an acute hospital or care home [25]. Many peo-
ple with dementia are admitted to care homes from the
acute hospital [26]. In the acute hospital setting, people
with dementia have poor outcomes; they have longer hos-
pital stays [27], an increased risk of not returning home
[26], and high mortality [28].
Population data from England show that around 20% of
people with dementia die annually [29]. Those admitted to
the acute hospital are at higher risk of death with the mortal-
ity rate in the year after admission approximately 40%
[27,30]. By examining the population with dementia who
are at highest risk of death, we aim to target our study of
the effects of medication on this enriched population. The
aim is to examine the association between treatment with
antidementia medication and mortality in this high-risk
group, that is, older people with dementia after an emer-
gency admission to the acute hospital.2. Methods
2.1. Population and data
National population–based health care data sets were used
to identify all residents of two Scottish Health Board regions
(Tayside and Fife) with known dementia, aged 65 years and
older, admitted to hospital as a medical emergency between
1/1/10 and 31/12/16. NHS Tayside and Fife provide care to
a diverse rural and urban area with a population in 2017 of
w775,000 which is approximately 14% of the population
of Scotland [31]. The configuration of service provision for
unscheduled emergency medical admissions of adults is via
acute medical units with subsequent discharge or step down
to appropriate medical wards after 12–24 hours.
An incident emergency admission cohort was selected to
study those patients at the outset of their interaction with
acute hospital services. This cohort was defined as those pa-
tients with a first emergency admission during the seven-
year study period after the dementia diagnosis in those
aged65 on admission, with no previous emergency admis-
sion in the preceding year. Mortality was ascertained within
the first year of follow-up from the date of the emergency
admission.
People with dementia were identified based on the Inter-
national Classification of Diseases (ICD-10) codes from
Scottish Morbidity Records (SMR01 and SMR04), which
are validated NHS Scotland routine data sets for general ad-
missions and psychiatric admissions, respectively, and the
community prescribing data. The latter data set was also
used to identify people, who were in receipt of a licensed
medication for dementia, and the duration of treatment.
Two classes of antidementia medication were considered:
AChEIs (donepezil, galantamine, and rivastigmine) and
memantine.
Data for incident emergency admissions were identified
from SMR01 data providing also admission and discharge
dates and destinations (whether care home or private
home) and discharge diagnosis (based on ICD-10 codes).
Discharge diagnosis from all previous admissions was
used to calculate each participant’s comorbidities for case-
mix adjustment. Thirteen comorbidities (excluding demen-
tia) were considered for adjustment as described in the study
by Quan et al. [32]; however, liver disease, paraplegia and
hemiplegia, and AIDS were present in less than 1% of the
incident cohort and so they were not included in the analysis.
Data on all community-dispensed prescriptions were
used to create an additional multimorbidity score, calculated
as the number of drugs (defined as the number of distinct
British National Formulary subsections) prescribed to the
patient 12 weeks before admission [33]. The community-
dispensed prescribing data were also used to identify pre-
scribed anticholinergic and sedative medication to calculate
an anticholinergic burden (ACB) score for the same time
period [34].
Fig. 1. Antidementia prescribing rates before/on admission and after admission (analysis undertaken under the ITT principle). Abbreviations: AChEIs, acetyl-
cholinesterase inhibitors; ITT, intention-to-treat.
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Scotland population based on General Practice registration)
was used to ascertain mortality and to define participant age,
sex, and postcode-defined socioeconomic status (measured
using quintiles of the Scottish Index of Multiple Depriva-
tion) on admission [35]. The CHI number (the NHS Scotland
unique patient identifier) was used to deterministically link
SMR01 to CHI, SMR04, and community-dispensed pre-
scribing.
2.2. Primary outcome, treatment, and control groups
The primary outcome of the study was time to death
within one-year follow-up from the incident emergency
admission, with mortality being ascertained from patient
date of death provided in the CHI records.
To examine associations between antidementia drugs pre-
scribing and outcomes in people admitted as medical
emergencies, the treatment group was defined by
intention-to-treat and included patients that were in receipt
of antidementia medication before admission, on admission,
or after admission. Specifically, the treatment group was
divided into patients that were prescribed AChEIs only,
memantine only, or both classes before, on or after admis-
sion (Fig. 1). The reference/control group included all re-
maining patients who were not even in receipt of an
antidementia medication. Some patients in the treatment
group were in receipt of antidementia medication before
admission but this was not continued at the time of their
admission or after admission; therefore, a secondary anal-
ysis was undertaken with the treatment group just including
patients that were in receipt of antidementia medication at
the time of their admission (defined as antidementia drug
prescribed within the 12 weeks before admission) or after
their admission.2.3. Statistical analysis
Summary statistics based on proportions and their confi-
dence intervals were used to estimate the distribution of pa-
tients that were in receipt of antidementia medication before
or on admission (a binary variable indicating whether pa-
tients were prescribed either an AChEIs or memantine, or
both before the incident emergency admission) according
to their demographic characteristics, comorbidities, and pol-
ypharmacy. In addition, patients who were in receipt of anti-
dementia medication on admission (defined as patients being
prescribed an antidementia drug in the 12 weeks before
admission) or started medication after admission were re-
corded separately. Associations between the rate of antide-
mentia drug prescribing and patients’ demographic
characteristics, comorbidity, community prescribed drugs,
and health board were examined with chi-square tests for as-
sociation.
Associations between antidementia drug prescribing and
time to mortality within one-year follow-up from admission
were examined using a Cox proportional-hazards survival
model. The Cox proportional-hazards model investigates
the relationship of predictors and the time-to-event, in this
case death. It assumes that the predictors have a multiplica-
tive effect on the hazard and that this effect is constant over
time. Also, owing to the regression framework of the model,
hazard ratio estimates that are controlled for other covariates
are possible. In this case, adjustment for demographics, co-
morbidity and community prescribing, ACB score, admis-
sion time, and type of emergency admission was
undertaken. Assessment of the proportional-hazards
assumption [36] showed that some Cox model covariates
did not meet this assumption; therefore, for these covariates,
piecewise constant time-varying coefficients were fitted to
the data to estimate changes in hazard ratios over time [37].
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not in receipt of antidementia drugs before admission had
antidementia medication started after discharge. The Cox
model allowed a time-varying covariate to be used to ac-
count for the time when people were initiated to antidemen-
tia treatment after admission within the one-year follow-up
period. Analysis was undertaken on an intention-to-treat ba-
sis.
2.4. Sensitivity analysis
To reduce the effect of treatment selection bias on the pri-
mary and secondary outcomes, propensity scores were
calculated for each patient defined as the probability to be
prescribed antidementia medication based on a patient’s de-
mographic characteristics, comorbidities, community pre-
scribing information, and whether the emergency
admission was an injury or noninjury admission. Propensity
score matching was then used to match each patient in the
treatment group that was in receipt of AChEI, or memantine,
or both types of drugs to a patient in the reference group. Pa-
tients were matched on the logit of propensity score using a
caliper of 0.2 standard deviations of the logit of the propen-
sity score [38]. Patients whowere initiated to any antidemen-
tia drug after discharge were excluded from the cohort
before propensity score matching.
A subgroup analysis was conducted separately for the two
health-board areas and for patients aged under 85 years to
assess the sensitivity of the main results as compared to sub-
group results.
Data analysis was carried out using SAS 9.4 (SAS Insti-
tute Inc., Cary, NC, USA).3. Results
3.1. Describing the cohort
Between January 2010 and December 2016, there were
27,703 emergency admissions of patients with dementia
aged 65 years and over in Tayside and Fife, of which 9142
were incident emergency admissions. Patients with an inci-
dent emergency admission were on average 84.2 (95% CI
84.1–84.3) years old, 63.6% (95% CI 62.6–64.6) were
women and 23.4% (95% CI 22.6–24.3) were admitted
from a care home.
At the time of emergency admission 39.1% (95% CI
38.1–40.1) of patients in the incident cohort were in receipt
of antidementia medication. In addition, 5.9% (95% CI 5.4–
6.4) had been in receipt of antidementia medication before
admission but not on admission, and 4.5% (95% CI 4.1–
4.9) were initiated antidementia medication after discharge
and within the one-year follow-up time, giving a total of
49.5% of the cohort being exposed to at least one antidemen-
tia drug either before or after admission (Fig. 1,
Supplementary Table 1). Before or on admission, 31.3%
(95% CI 30.4–32.3) of patients were prescribed only
AChEIs, 8.7% (95% CI 8.2–9.3) only memantine, and4.9% (95% CI 4.5–5.4) both classes (Table 1); 46.6% of
men were in receipt of antidementia medication before or
on admission as compared to 44% of women (difference
2.6%, 95% CI 0.9–5.1, chi-square P value 5 .016). People
in receipt of antidementia medication were significantly
younger than those receiving no medication (83.2 years vs.
85.0 years on average, difference 1.8 years 95% CI 1.5–
2.0, t-test P value , .001). Only 39.1% of people in the
851 age group were in receipt of antidementia medication
before or on admission compared to 53.7% in the 70 to 74
age group (Table 2). 36.5% of people admitted from care
homes were in receipt of antidementia drug, as compared
to 47.5% of people admitted from private home (difference
11.0%, 95% CI 8.6–13.3, P value , .001). Antidementia
drug prescribing before or on admission was significantly
associated with social deprivation with 49.1% versus
43.0% antidementia prescribing rates in least deprived areas
SIMD 5 5 versus medium class areas of deprivation
SIMD 5 3 (chi-square P value 5 .003). Among the 10 co-
morbidities considered, the antidementia drug prescribing
rate was significantly associated with peripheral vascular
disease, cerebrovascular disease, and chronic pulmonary
disease (all chi-square P values , .001), with lower
prescribing rates being found in people with these comorbid-
ities. Antidementia drug prescribing before or on admission
was also significantly associated with a patient’s number of
drugs in the 12 weeks before admission (P value , .001),
and the ACB score in the 12 weeks before admission (P
value 5 .015).3.2. Analysis of primary outcome: Time to death in the
year after admission
In the year after admission, 38.28% (n 5 3500) of pa-
tients had died; 32.90% (n 5 1352) of patients receiving
antidementia medication before or on admission died in
the year after admission, compared to 42.7% (n 5 2148)
of those not receiving antidementia medication before or
on admission.
Table 2 shows the associations between antidementia
drug exposure and mortality within one year from admis-
sion based on intention-to-treat analysis. The results of the
Cox model show that after adjustment for demographic
characteristics, comorbidities, prescribing, and emergency
type, presence of antidementia treatment was significantly
associated with a reduction in mortality risk at one year,
for both classes of drugs. Specifically, patients in receipt
of AChEIs were at a significantly reduced risk of death
at one year (HR 5 0.78, 95% CI 0.72–0.85), as were pa-
tients who were in receipt of memantine alone
(HR 5 0.75, 95% CI 0.66–0.86) or patients who were
receiving both classes (HR 5 0.80, 95% CI 0.68–0.94).
These results were further confirmed by the secondary
analysis, which showed even stronger association between
antidementia medication treatment and mortality when
only people in receipt of antidementia drug on or after
Table 1
Antidementia medication prescribing rates before or on admission based on patient’s characteristics
Patients’ characteristics
Any antidementia
medication (n 5 4110)
AChEIs only
(n 5 2864)
Memantine only
(n 5 798)
Both classes
(n 5 448)
All patients (n 5 9142) 45.0 (44.0–46.0) 31.3 (30.4–32.3) 8.7 (8.1–9.3) 4.9 (4.5–5.4)
Sex
Female (n 5 5816) 44.0 (42.7–45.3) 31.7 (30.5–31.7) 7.7 (7.0–8.4) 4.5 (4.0–5.1)
Male (n 5 3326) 46.6 (44.9–48.3) 30.6 (29.1–32.2) 10.5 (9.5–11.6) 5.5 (4.8–6.3)
Age group
65–69 (n 5 76) 47.4 (36.6–58.5) 36.8 (26.8–48.0) 4.0 (1.4–11.0) 6.6 (2.9–14.5)
70–74 (n 5 607) 53.7 (49.7–57.6) 36.6 (32.9–40.5) 10.2 (8.0–12.9) 6.9 (5.1–9.2)
75–79 (n 5 1431) 50.8 (48.2–53.4) 35.4 (33.0–37.9) 8.3 (7.0–9.8) 7.2 (6.0–8.7)
80–84 (n 5 2451) 50.3 (48.3–52.3) 34.6 (32.7–36.5) 9.7 (8.6–10.9) 6.0 (5.1–7.0)
851 (n 5 4577) 39.1 (37.7–40.5) 27.5 (26.2–28.8) 8.2 (7.4–9.0) 3.3 (2.8–3.9)
Residential status
Care home (n 5 2143) 36.5 (34.5–38.6) 23.3 (21.6–25.1) 7.8 (6.7–9.0) 5.5 (4.6–6.5)
Living at home (n 5 6999) 47.5 (46.3–48.7) 33.8 (32.7–34.9) 9.0 (8.4–9.7) 4.7 (4.2–5.2)
SIMD5*
1 most deprived (n 5 1275) 44.2 (41.5–46.9) 27.1 (24.7–29.6) 12.7 (11.0–14.6) 4.4 (3.4–5.7)
2 (n 5 1571) 45.5 (43.1–48.0) 28.3 (26.1–30.6) 11.4 (9.9–13.1) 5.7 (4.7–7.0)
3 (n 5 1869) 43.0 (40.8–45.3) 29.6 (27.6–31.7) 8.5 (7.3–9.9) 4.9 (4.0–6.0)
4 (n 5 2664) 43.6 (41.7–45.5) 33.3 (31.5–35.1) 6.3 (5.4–7.3) 4.0 (3.3–4.8)
5 least deprived (n 5 1601) 49.1 (46.7–51.5) 36.7 (34.4–39.1) 6.9 (5.8–8.2) 5.5 (4.5–6.7)
Health board
Fife (n 5 4590) 52.2 (50.8–53.6) 29.8 (28.5–31.1) 15.5 (14.5–16.6) 6.9 (6.2–7.7)
Tayside (n 5 4592) 37.7 (36.2–39.0) 32.9 (31.6–34.3) 1.9 (1.5–3.4) 2.9 (2.5–3.4)
Comorbiditiesy
Myocardial infarction (n 5 735) 42.9 (39.4–46.5) 25.4 (22.4–28.7) 13.9 (11.6–16.6) 3.5 (2.4–5.1)
Congestive heart failure (n 5 615) 37.9 (34.2–41.8) 22.6 (19.5–26.1) 12.4 (10.0–15.2) 2.9 (1.8–4.5)
Peripheral vascular disease (n 5 399) 37.1 (32.5–41.9) 21.1 (17.4–25.4) 12.0 (9.2–15.6) 4.0 (2.5–6.4)
Cerebrovascular disease (n 5 1324) 34.4 (31.9–37.0) 22.0 (19.9–24.3) 9.5 (8.0–11.2) 2.9 (2.1–3.9)
Chronic pulmonary disease (n 5 1107) 38.9 (36.1–41.8) 23.7 (21.3–26.3) 12.7 (10.9–14.8) 2.6 (1.8–3.7)
Peptic ulcer disease (n 5 135) 40.7 (32.8–49.1) 24.4 (17.9–29.6) 15.6 (10.4–22.7) 0.7 (0.1–4.0)
Rheumatic disease (n 5 198) 35.4 (29.1–42.3) 23.2 (17.9–29.6) 9.1 (5.8–13.9) 3.0 (1.4–6.4)
Diabetes (n 5 1280) 41.4 (38.7–44.1) 27.4 (25.0–29.9) 9.1 (7.6–10.8) 4.8 (3.8–6.1)
Renal disease (n 5 1186) 42.6 (39.8–45.4) 26.7 (24.3–29.3) 11.6 (9.9–13.5) 4.3 (3.3–5.6)
Cancer (n 5 717) 44.1 (40.5–47.8) 30.1 (26.9–33.6) 9.9 (7.9–12.3) 4.0 (2.8–5.7)
No. of drugsz
0 (n 5 987) 36.5 (33.6–39.6) 26.8 (24.1–29.6) 4.1 (3.0–5.5) 5.7 (4.4–7.3)
1–5 (n 5 5103) 47.1 (45.7–48.6) 33.0 (31.7–34.3) 8.9 (8.1–9.7) 5.3 (4.7–5.9)
61 (n 5 3052) 44.1 (42.3–45.9) 30.1 (28.5–31.8) 10.0 (9.0–11.9) 4.0 (3.4–4.8)
ACB scorex
0 (n 5 5834) 44.3 (43.0–45.6) 31.7 (30.5–32.9) 8.3 (7.6–9.0) 4.4 (3.9–5.0)
1–2 (n 5 2235) 47.5 (45.4–49.6) 30.7 (28.8–32.6) 10.6 (9.4–11.9) 6.2 (5.3–7.3)
31 (n 5 1073) 43.1 (40.2–46.1) 30.8 (28.1–33.6) 7.4 (6.0–9.1) 4.9 (3.8–6.4)
Emergency type
Noninjury (n 5 7356) 44.6 (43.5–45.7) 30.8 (29.8–31.9) 8.9 (8.3–9.6) 4.9 (4.4–5.4)
Injury (n 5 1786) 46.4 (44.1–48.7) 33.4 (31.3–35.6) 8.0 (6.8–9.4) 4.9 (4.0–6.0)
Abbreviations: AChEIs, acetylcholinesterase inhibitors; ACB, anticholinergic burden; ICD-10, International Classification of Diseases.
*Scottish Index of Multiple Deprivation divided into five quintiles, 162 values are missing.
yComorbidity based on ICD-10 codes in SMR01 data set.
zNumber of drugs prescribed during the 12 weeks before admission.
xAnticholinergic burden score during the 12 weeks before admission.
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(Supplementary Materials Table S1).
Male sex, increased age, and residency in a care home
were all associated with increased risk of death. The pres-
ence of comorbid conditions such as congestive heart failure,
peripheral vascular disease, cerebrovascular disease, chronic
pulmonary disease, renal disease, and cancer were all
significantly associated with an increased risk of death
during follow-up. Myocardial infarction was significantlyassociated with an increase in mortality risk only in the first
30 days from admission. No significant associations were
found between peptic ulcer disease, rheumatic disease, or
diabetes and increased mortality (HRs in Table 2). Further-
more, an increase in number of drugs prescribed 12 weeks
before admission was significantly associated with an in-
crease in mortality risk, while ACB score was not signifi-
cantly associated with an increased mortality (HRs in
Table 2). No significant difference in mortality risks at one
Table 2
Unadjusted and adjusted HR estimates of Cox model with time-varying covariates for associations between antidementia drug prescribing and mortality with
one-year follow-up from admission based on the ITT principle
Patients’ characteristics Model variables Time period
Unadjusted model
HR and 95% CI
Adjusted model
HR and 95% CI
Antidementia
medication
AChEIs versus no medication 0.65 (0.60–0.70) 0.78 (0.72–0.85)
Memantine versus no medication 0.74 (0.65–0.83) 0.75 (0.66–0.86)
Both classes versus no medication 0.68 (0.58–0.79) 0.80 (0.68–0.94)
Sex Male versus female Up to 90 days 1.14 (1.04–1.24) 1.15 (1.05–1.27)
90 days to 1 year 1.40 (1.26–1.54) 1.47 (1.33–1.63)
Age Per 5 years 1.20 (1.17–1.23) 1.19 (1.16–1.22)
Residence status Care home versus private home Up to 30 days 2.46 (2.16–2.79) 2.57 (2.27–2.91)
30 days to 1 year 1.77 (1.61–1.95) 1.82 (1.66–2.00)
Health board Fife versus Tayside 1.06 (0.99–1.13) 1.04 (0.97–1.12)
SIMD5* 1 versus 5 (most vs. least deprived) 1.05 (0.95–1.17) -
2 versus 5 1.00 (0.91–1.10) -
3 versus 5 1.00 (0.91–1.10) -
4 versus 5 0.96 (0.89–1.05) -
Comorbiditiesy Myocardial infarction Up to 30 days 1.53 (1.27–1.84) 1.30 (1.07–1.57)
(presence vs. absence) 30 days to 1 year 1.05 (0.90–1.22) 0.86 (0.74–1.00)
Congestive heart failure 1.70 (1.52–1.91) 1.46 (1.29–1.64)
Peripheral vascular disease 1.83 (1.60–2.09) 1.67 (1.46–1.91)
Cerebrovascular disease Up to 30 days 1.69 (1.46–1.95) 1.46 (1.26–1.69)
30 days to 1 year 1.30 (1.17–1.45) 1.19 (1.06–1.33)
Chronic pulmonary disease 1.15 (1.04–1.27) 1.11 (1.01–1.23)
Peptic ulcer disease 1.10 (0.84–1.43) -
Rheumatic disease 0.98 (0.78–1.23) -
Diabetes 1.01 (0.92–1.11) -
Renal disease 1.42 (1.29–1.55) 1.13 (1.08–1.18)
Cancer—early stage 1.68 (1.49–1.89) 1.66 (1.47–1.87)
Cancer—metastatic 3.38 (2.84–4.02) 3.77 (3.16–4.49)
No of drugs groupsz 1 to 5 1.08 (0.96–1.21) 1.11 (0.99–1.25)
61 1.21 (1.07–1.35) 1.14 (1.00–1.29)
ACB groupsx ACB 1 & 2 1.14 (1.05–1.23) 1.07 (0.98–1.15)
ACB 31 1.03 (0.92–1.14) 0.97 (0.87–1.08)
Admission time Per year Up to 30 days 0.94 (0.91–0.96) 0.94 (0.91–0.97)
30 days to 1 year 1.01 (0.99–1.03) 1.01 (0.99–1.03)
Emergency type Injury versus noninjury Up to 30 days 0.46 (0.38–0.56) 0.43 (0.36–0.53)
30 days to 1 year 0.80 (0.71–0.91) 0.84 (0.76–0.93)
NOTE. HR estimates were adjusted for demographic characteristics, comorbidities, community prescribing drugs including ACB, admission time, and type
of emergency admission.
Abbreviations: AChEIs, acetylcholinesterase inhibitors; ACB, anticholinergic burden; HR, hazard ratio; ICD-10, International Classification of Diseases;
ITT, intention-to-treat.
*Scottish Index of Multiple Deprivation divided into five quintiles, 162 values are missing.
yComorbidity based on ICD-10 codes in SMR01 data set.
zNumber of drugs prescribed during the 12 weeks before admission.
xAnticholinergic burden score during the 12 weeks before admission.
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ciation between patients’ demographic, comorbidities, pre-
scribing and emergency type, and mortality was found by
the secondary analysis as shown in the Supplementary
Table 1.3.3. Sensitivity analysis
The propensity score matching analysis results were
consistent with the main results presented previously
(Table 3). Indeed, analysis of one-year survival time
showed a significant reduction in mortality risk for peoplein receipt of antidementia drugs on admission, with the
highest reduction in those that were in receipt of both
drug classes.
The subgroup analysis for the regions of Fife and Tayside
and for those under 85 years were consistent with the anal-
ysis of main results (Table 3), with the exception of Tayside,
where due to small number of patients under receipt of mem-
antine either alone or combined with AChEI, time to mortal-
ity in these treatment groups was not significantly different
as compared to those untreated with antidementia medica-
tion although the HR was of the same order of magnitude
as the full analysis.
Table 3
Sensitivity analysis results for associations between antidementia drugs and
patients’ outcomes after an emergency admission after propensity score
matching
Sensitivity
analysis Treatment
ITT analysis (antidementia
medication before or on admission)
Un-adjusted Adjusted
Propensity
score
matching
AChEI only 0.74 (0.67–0.82) 0.73 (0.66–0.81)
Memantine
only
0.78 (0.66–0.92) 0.79 (0.66–0.92)
Both classes 0.72 (0.54–0.96) 0.69 (0.51–0.93)
Subgroup
analysis
84 years old
or less
AChEI only 0.67 (0.59–0.75) 0.78 (0.69–0.88)
Memantine
only
0.70 (0.58–0.85) 0.70 (0.58–0.85)
Both classes 0.75 (0.61–0.92) 0.82 (0.66–1.01)
Subgroup
analysis Fife
region
AChEI only 0.67 (0.60–0.75) 0.84 (0.74–0.94)
Memantine
only
0.71 (0.62–0.81) 0.77 (0.66–0.87)
Both classes 0.69 (0.57–0.83) 0.80 (0.66–0.97)
Subgroup
analysis
Tayside region
AChEI only 0.63 (0.56–0.70) 0.73 (0.66–0.81)
Memantine
only
0.73 (0.51–1.03) 0.80 (0.56–1.13)
Both classes 0.62 (0.46–0.82) 0.80 (0.59–1.07)
NOTE. Subgroup analysis results for those aged 84 years and younger,
and those from region of Fife and Tayside.
Abbreviations: AChEI, acetylcholinesterase inhibitor; ITT, intention-to-
treat.
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Mortality is high in the population with dementia
admitted to the acute hospital; over one third of patients
died in the year after admission. Forty-five percent
(n5 4110) of patients were in receipt of antidementia medi-
cation before or on admission, with 31.3% (n5 2864) being
prescribed one of the AChEIs, 8.7% (n 5 798) memantine,
and 4.9% (n 5 448) both classes; 32.90% (n 5 1352) of
these patients died in the year after admission, compared
to 42.7% (n 5 2148) of those not receiving antidementia
medication on admission.
Previous studies have reported associations between anti-
dementia drug use and reduced mortality in the community
[18,21–23,39,40]. There is no previous reporting on
associations between antidementia treatment and mortality
after admission in this high-risk population of in-patients.
People with dementia experience poor outcomes after hospi-
talization, with higher mortality than people with no demen-
tia [27,28]. The present study shows for the first time that
treatment with antidementia drugs is associated with
reduced mortality in the population with dementia. This
associated reduction is of the scale that for every 100
patients treated, 10 or fewer would die in the year after
admission.
Reduced susceptibility to cardiovascular deaths has been
postulated as a possible explanation [41], with one cohort
study finding an associated reduction in cardiovascular
deaths in people with dementia treated with ACheI [24].
With the ACheI having a direct effect on boostingacetylcholine levels in synapses and hence boosting neuro-
transmission, modification of this neuropharmacological
system is also a candidate when looking at possible explana-
tions to this association with reduced mortality.
Increased anticholinergic burden has been associated
with increased risk of mortality in older patients [42]. Asso-
ciations have been identified between anticholinergic medi-
cations and increased dementia risk [43] and between
anticholinergic burden and mortality in people with demen-
tia [44]. Our results did not identify an association between
anticholinergic burden and mortality risk in patients with de-
mentia. There was however an association with polyphar-
macy, known to be common in those with dementia [45],
and mortality. Frailty has been associated with polyphar-
macy, although the impact of the association requires further
exploration [46]. With the findings that mortality in people
with dementia is not associated with disease severity, cogni-
tive function, or functional ability [2], we can postulate that
comorbidity and frailty may play a role in determining mor-
tality risk and that it may be via this route that antidementia
medication treatment attenuates mortality risk. Of note,
expert-derived tools to target polypharmacy in frail older
adults could not reach consensus around continuation or
stopping antidementia medications, suggesting variation in
clinical practice [47].
An important strength of the study is the use of a large,
unselected population of peoplewith dementia aged 65 years
and over admitted to hospital as a medical emergency, using
routine health care national data. To date, this is the largest
study reporting on mortality after an emergency admission
of people with dementia from two health boards in Scotland.
The association between antidementia drug use and mortal-
ity is consistent between the two health boards. There are
some differences; in particular, we found that memantine
is prescribed rarely in Tayside (4.8%) compared to Fife
(22.4%). Because of the small number of patients under
receipt of memantine (either alone or combined with
AChEIs) in Tayside, time to mortality in these treatment
group was not significantly different as compared to those
free of antidementia medication. However, point estimates
of effect size of memantine showed very little difference be-
tween the two health boards, suggesting that there are un-
treated people with dementia that could potentially benefit
from the use of this medication.
The main limitation of this study is the potential selection
bias in the treatment group, which is characteristic of most
observational studies reporting associations between drug
use and outcomes. In the case of antidementia drugs, treat-
ment selection bias can be particularly problematic given
that up until 2012, NICE guidance in the UK recommended
the use of antidementia medication in healthier patients [48].
To address this problem, we conducted a propensity score
matching analysis, where patients in receipt of antidementia
drug treatment were matched against patients with similar
characteristics that were not receiving treatment. The anal-
ysis showed results consistent with the main results analysis
S. Hapca et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 431-440438after adjustment for patients’ characteristics, though with
perhaps more realistic clinical effects, having reduced con-
founding. Model estimates were adjusted for patient’s demo-
graphics, comorbidities, and community prescribing drugs,
but no information was available on their functional status
or the level of cognitive impairment, although adjusting
for these additional factors is debatable due to the risk of
overadjustment due to collinearity.5. Conclusions
Mortality in older people admitted with dementia is very
high after an emergency hospital admission [28], and we
suggest that the population experiencing an acute hospital
admission is at increased risk of death compared to those
with dementia living in the community. In this study, we
show that even in this high-risk population, mortality in peo-
ple with dementia after a hospital admission is lower in those
patients treated with antidementia medication. This finding
could be consistent with the suggestion that these classes
of medication afford some disease-modifying effect for peo-
ple with dementia, and postulated mechanisms include
reducing cardiovascular deaths and/or attenuating the detri-
mental effects of comorbidity and frailty. Further research is
required to replicate these findings, to determine direct
causal relationships between the use of antidementia medi-
cation and mortality and to directly elucidate plausible
mechanisms for the effects.
Having examined one clinically relevant outcome, mor-
tality, for this study, it does also raise the question as to
whether other clinically relevant outcomes (e.g., functional
ability or need for long-term care) are modulated in associ-
ation with dementia treatment in the real-world setting.Acknowledgments
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1. Systematic review: The authors searched PubMed
for studies that investigated associations between
antidementia drugs and mortality in the older popula-
tion with dementia, with previous research reporting
conflicting evidence in this respect. There is no pre-
vious report on associations between antidementia
treatment and mortality after hospital admission in
this population.
2. Interpretation: Mortality in older people admitted
with dementia is very high after an emergency hospi-
tal admission. However, more than half of the older
patients admitted with dementia are not in receipt
of any antidementia treatment. Our finding suggests
that risk of death is reduced in those patients treated
with antidementia medication, either anticholines-
terase inhibitors, or memantine or both, which is
consistent with some disease-modifying effect of
these classes of medication.
3. Future directions: Further research is required to
determine direct causal relationships between the
use of antidementia medication and mortality in peo-
ple with dementia.References
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